Status:
RECRUITING
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
Lead Sponsor:
First Affiliated Hospital of Chongqing Medical University
Conditions:
PSMA
FAP
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the saf...
Eligibility Criteria
Inclusion Criteria:
- At least 18 years of age.
- Signed informed consent.
- Patients with suspected or newly diagnosed or previously malignant disease, with either PSMA or FAP positive expression (supporting evidence may include MRI, CT, and pathology report, etc).
Exclusion Criteria:
- Patients with non-malignant disease.
- Patients with pregnancy.
- The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
- Known or expected hypersensitivity to 68Ga-PSFA or any of its components.
- Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Key Trial Info
Start Date :
May 20 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06387381
Start Date
May 20 2024
End Date
December 31 2026
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016